acr-368
Generic: prexasertib·Code: ACR-368
acr-368: sourced relationships with 1 company · 1 clinical trial tracked.
acr-368 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect acr-368 to ACRV; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could acr-368 → ACRV affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Endometrial Adenocarcinoma
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Acrivon Therapeutics, Inc. (ACRV) Endometrial Adenocarcinoma | Phase 2 |
Clinical Trial Registry Records (1)
A Phase 2 Study of ACR-368 Therapy in Subjects With Endometrial Cancer
Primary endpoint: Arm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive.
Interventionalopen350 targetStarted 2022-08Completion 2027-1150 sites · United StatesAcrivon Therapeutics
Frequently asked questions
Which companies have sourced relationships with acr-368?
acr-368 has dated SEC/FDA relationship records for Acrivon Therapeutics, Inc..
How many clinical trials involve acr-368?
BioSniper tracks 1 clinical trial involving acr-368.